Can a simple eye treatment stop the need for a corneal transplant?

NCT ID NCT00560651

Ongoing Disease control Sponsor: Suphi Taneri Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry collects long-term data from hundreds of people in Germany who have undergone corneal cross linking for keratoconus, a condition where the cornea thins and bulges, causing vision loss. The procedure uses riboflavin (vitamin B2) eye drops and UV light to stiffen the cornea and stop the disease from getting worse. The goal is to see whether this treatment can prevent the need for a corneal transplant over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Corneal cross linking (riboflavin plus UV light)
What this could lead to: If successful, this registry could confirm that corneal cross linking stops keratoconus from worsening and reduces the need for corneal transplants.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Rare complications or limited long-term data may affect conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal disorder keratoconus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KERATOCONUS

Contacts and locations

Locations

Augenklinik am St. Franziskus Hospital

Münster, 48145, Germany
University of Saar

Homburg, 66421, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.